|
1
|
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.
|
J Natl Cancer Inst
|
2004
|
14.97
|
|
2
|
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
|
J Natl Cancer Inst
|
2012
|
2.21
|
|
3
|
Physician use of genetic testing for cancer susceptibility: results of a national survey.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
1.83
|
|
4
|
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.66
|
|
5
|
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
|
Breast Cancer Res Treat
|
2012
|
1.66
|
|
6
|
Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration.
|
J Clin Epidemiol
|
2011
|
1.46
|
|
7
|
Prevalence and correlates of repeat mammography among women aged 55-79 in the Year 2000 National Health Interview Survey.
|
Prev Med
|
2004
|
1.39
|
|
8
|
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.
|
Genet Med
|
2012
|
1.39
|
|
9
|
What factors are associated with diagnostic follow-up after abnormal mammograms? Findings from a U.S. National Survey.
|
Cancer Epidemiol Biomarkers Prev
|
2004
|
1.36
|
|
10
|
Awareness of genetic testing for increased cancer risk in the year 2000 National Health Interview Survey.
|
Community Genet
|
2003
|
1.36
|
|
11
|
Communication of uncertainty regarding individualized cancer risk estimates: effects and influential factors.
|
Med Decis Making
|
2010
|
1.33
|
|
12
|
Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population.
|
Pharmacoepidemiol Drug Saf
|
2013
|
1.33
|
|
13
|
Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey.
|
Genet Med
|
2010
|
1.26
|
|
14
|
Laypersons' responses to the communication of uncertainty regarding cancer risk estimates.
|
Med Decis Making
|
2009
|
1.15
|
|
15
|
Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
1.13
|
|
16
|
Conceptual problems in laypersons' understanding of individualized cancer risk: a qualitative study.
|
Health Expect
|
2009
|
1.12
|
|
17
|
Genome-based prediction of breast cancer risk in the general population: a modeling study based on meta-analyses of genetic associations.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
1.09
|
|
18
|
Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research.
|
J Natl Cancer Inst
|
2012
|
1.04
|
|
19
|
Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
|
Clin Cancer Res
|
2005
|
1.03
|
|
20
|
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.
|
J Natl Cancer Inst
|
2013
|
0.98
|
|
21
|
Representing randomness in the communication of individualized cancer risk estimates: effects on cancer risk perceptions, worry, and subjective uncertainty about risk.
|
Patient Educ Couns
|
2011
|
0.98
|
|
22
|
Frontiers in cancer epidemiology: a challenge to the research community from the Epidemiology and Genomics Research Program at the National Cancer Institute.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.97
|
|
23
|
Correlates of unrealistic risk beliefs in a nationally representative sample.
|
J Behav Med
|
2010
|
0.95
|
|
24
|
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.
|
Eur J Epidemiol
|
2011
|
0.94
|
|
25
|
Physician exposure to and attitudes toward advertisements for genetic tests for inherited cancer susceptibility.
|
Am J Med Genet A
|
2005
|
0.91
|
|
26
|
Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.
|
Drug Saf
|
2012
|
0.90
|
|
27
|
Five-year and lifetime risk of breast cancer among U.S. subpopulations: implications for magnetic resonance imaging screening.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.88
|
|
28
|
The impact of changes in hormone therapy on breast cancer incidence in the US population.
|
Cancer Causes Control
|
2009
|
0.85
|
|
29
|
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.
|
Eur J Clin Invest
|
2011
|
0.85
|
|
30
|
Dosing recommendations for pharmacogenetic interactions related to drug metabolism.
|
Pharmacogenet Genomics
|
2016
|
0.80
|
|
31
|
Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature.
|
Expert Opin Drug Saf
|
2014
|
0.80
|
|
32
|
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.
|
Eur J Hum Genet
|
2011
|
0.79
|
|
33
|
Epidemiology--found in translation.
|
Cancer Discov
|
2011
|
0.77
|